Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 6c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story
• KeyBanc lowers Nike rating to Sector Weight on near-term uncertainty
• Argus starts SpaceX at Hold, sees record IPO as a multi-year re-rating challenge